血清可溶性白细胞G抗原在宫颈癌及癌前病变的临床诊断意义  

Clinical diagnostic value of plasma sHLA-G antigen in cervical cancer and precancerous lesion

作　　者：田玫玲[1] 卢庆乐[1] 

机构地区：[1]山东大学附属省立医院检验科,山东济南250022

出　　处：《国际检验医学杂志》2015年第7期889-891,共3页International Journal of Laboratory Medicine

摘　　要：目的探讨血清可溶性白细胞G抗原(sHLA-G)在宫颈癌及癌前病变中的临床诊断价值。方法用酶联免疫吸附法(ELISA)法测定同期230例宫颈癌患者、120例宫颈上皮内瘤样变(CIN)患者及30例健康自愿者的血清sHLA-G水平及电化学免疫发光法测定血清中宫颈癌相关抗原(TA-4)和SCC-Ag水平,分析其在各组间的差异及与宫颈癌临床病理特征之间的关系。结果 (1)血清中sHLA-Ag、TA-4及鳞形细胞癌相关抗原(SCC-Ag)水平的比较:血清sHLA-G浓度各组间的差异有统计学意义(P=0.000);宫颈癌组明显高于对照组和CIN各组(P=0.000,P=0.000,P=0.002,P=0.006);CINⅢ级组明显高于CINⅠ级组和对照组(P=0.001,P=0.021)。各组间血清TA-4浓度的差异有统计学意义(P=0.006);宫颈癌组明显高于对照组、CINⅠ级组和CINⅡ级组(P=0.003,P=0.008,P=0.018);CINⅢ级组明显高于对照组与CINⅠ级组(P=0.023,P=0.031)。各组间血清SCC-Ag浓度间的差异有统计学意义(P=0.000);宫颈癌组明显高于对照组、CINⅠ级组与CINⅡ级组(P=0.000,P=0.001,P=0.007);CINⅢ级组明显高于对照组和CINⅠ级组(P=0.013,P=0.021)。(2)血清sHLA-G与宫颈癌病理特征的关系:宫颈癌患者血浆中sHLA-G水平与FIGO分期和淋巴结转移密切相关(P=0.008,P=0.031),而与患者年龄、肿瘤大小及病理类型无关(P>0.05)。宫颈癌FIGO分期Ⅲ、Ⅳ期患者的血清sHLA-G水平明显高于Ⅰ、Ⅱ期患者(U=7.125,P=0.008),伴淋巴结转移患者的血浆sHLA-G水平明显高于淋巴结转移阴性患者(U=4.651,P=0.031)。结论血清sHLA-G水平检测有助于宫颈癌及CINⅢ的早期诊断及病情评估,有可能成为一种新的早期诊断指标。但其与发生宫颈癌及癌前病变的特异性分析仍有待进一步的相关研究。Objective To explore the clinical diagnostic valve of serum soluble human leukocyte antigen-G（sHLA-G）in cervical cancer and precancerous lesion cervical intraepithelial neoplasia（CIN）.Methods The serum sHLA-G level was detected by using ELISA and serum TA-4and SCC-Ag levels were detected by using the light-emitting electrochemical immunoassay method detecting in 230 cases of cervical carcinoma,120 cases of CIN and 30 healthy volunteers.The differences among various groups and their relationship with the clinicopathological features of cervical cancer were analyzed.Results（1）The comparison of serum sHLA-G,TA-4and SCC-Ag levels：there were statistically significant differences in serum sHLA-G level among various groups（P=0.000）;the serum sHLA-G level in the cervical cancer group was significantly higher than that in the healthy control group,CIN Ⅰgroup,CIN Ⅱ group and CIN Ⅲ group（P=0.000,P=0.000,P=0.002,P=0.006）;which in the CIN Ⅲ group was significantly higher than that in the CIN Ⅰ group and the healthy control group（P=0.001,P=0.021）.There were statistically significant differences in serum TA-4level among various groups（P=0.006）;the serum TA-4level in the cervical cancer group was significantly higher than that in the healthy control group,CIN Ⅰ group and CIN Ⅱ group（P=0.003,P=0.008,P=0.018）;which in the CIN Ⅲgroup was significantly higher than that in the healthy control group and the CIN Ⅰ group（P=0.023,P=0.031）.The differences of serum SCC-Ag level among various groups had statistically significant differences（P=0.000）;which in the cervical cancer group was significantly higher than that in the healthy control group,CIN Ⅰ group and CIN Ⅱ group（P=0.000,P=0.001,P=0.007）,and which in the CIN Ⅲ group was significantly higher than that in the healthy control group and the CIN Ⅰ group（P=0.013,P=0.021）.（2）The relationship between serum sHLA-G and pathological features of cervical cancer：the serum sHLA-G level had no significant correlat

关 键 词：可溶性白细胞G抗原 宫颈癌 癌前病变 

分 类 号：R737.33[医药卫生—肿瘤]